Accelerating drug development at Bristol Myers Squibb through innovation

Area of Science:

• Pharmaceutical drug development
• Clinical trial innovation
• Health technology adoption

Background:

• Rising costs and complexities in pharmaceutical R&D necessitate innovative solutions.
• The need to accelerate the delivery of novel medicines to patients is paramount.
• External pressures demand increased efficiency in drug development pipelines.

Purpose of the Study:

• To summarize learnings from Bristol Myers Squibb's efforts in accelerating pharmaceutical R&D.
• To highlight the impact of novel technologies and innovative trial designs on R&D productivity.
• To provide case examples of successful R&D acceleration strategies.

Main Methods:

• Review of internal initiatives focused on R&D acceleration.
• Analysis of four key areas: innovative trial designs, trial design optimization, external control data utilization, and AI/ML implementation.
• Case study approach to illustrate practical application and learnings.

Main Results:

• Adoption of innovative trial designs has shown promise in accelerating evidence generation.
• Optimization of trial designs contributes to increased R&D productivity.
• Leveraging external control data and implementing AI/ML offers new avenues for efficiency.
• Successful evolution in addressing drug development challenges.

Conclusions:

• Novel technologies and innovative trial designs are crucial for accelerating pharmaceutical R&D.
• A strategic focus on design, data, and advanced methods enhances drug development efficiency.
• Continuous adaptation and evolution are key to overcoming industry challenges and delivering medicines faster.